GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2007

Psychogenics and Cephalon Ally on Neuropsychiatric Drug Discovery

  • PsychoGenics entered into a drug discovery agreement with Cephalon related to neuropsychiatric disorders. Cephalon will provide related compounds, while Psycogenics will evaluate these candidates.

    The companies will jointly identify those candidates suitable for clinical development. If either company decides to further develop any of these drugs, that firm will pay the other milestone and royalty fees .

    PsychoGenics' technologies combines in vivo behavioral expertise with robotics, computer vision, and bio/cheminformatics. The platform is used to evaluate potential therapies related to a number of neuropsychiatric disease indications.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »